Benjamin Palleiko Sells 10,926 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin Palleiko sold 10,926 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $26.78, for a total transaction of $292,598.28. Following the sale, the chief executive officer directly owned 479,989 shares in the company, valued at $12,854,105.42. The trade was a 2.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Stock Down 0.1%

Shares of KalVista Pharmaceuticals stock opened at $26.79 on Thursday. The company has a debt-to-equity ratio of 8.18, a quick ratio of 5.10 and a current ratio of 5.17. The stock has a market capitalization of $1.43 billion, a PE ratio of -7.74 and a beta of -0.12. KalVista Pharmaceuticals, Inc. has a 52-week low of $9.83 and a 52-week high of $26.85. The company has a 50-day simple moving average of $21.94 and a two-hundred day simple moving average of $17.65.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The business had revenue of $40.86 million for the quarter, compared to analyst estimates of $39.03 million. On average, analysts anticipate that KalVista Pharmaceuticals, Inc. will post -0.96 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Parallel Advisors LLC raised its holdings in shares of KalVista Pharmaceuticals by 45.8% during the first quarter. Parallel Advisors LLC now owns 1,876 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 589 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of KalVista Pharmaceuticals during the third quarter valued at approximately $55,000. Royal Bank of Canada raised its holdings in shares of KalVista Pharmaceuticals by 137.0% during the first quarter. Royal Bank of Canada now owns 2,917 shares of the specialty pharmaceutical company’s stock valued at $59,000 after purchasing an additional 1,686 shares during the last quarter. Finally, Truvestments Capital LLC raised its holdings in shares of KalVista Pharmaceuticals by 253.8% during the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,360 shares during the last quarter.

Analysts Set New Price Targets

Several brokerages have issued reports on KALV. Leerink Partners cut shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, April 21st. Wall Street Zen cut shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 21st. JonesTrading cut shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 30th. Finally, Stifel Nicolaus lifted their target price on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Three investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, KalVista Pharmaceuticals has an average rating of “Hold” and an average price target of $30.60.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.